LY500307 inhibits tumor growth progression in a CTCL xenograft mouse model. (A) NSG mice were xenografted with MyLa cells subcutaneously and treated once daily with either 10 mg/kg body weight of LY500307 per os or placebo (n = 12 each); mean tumor volume ± SD over time of subcutaneous MyLa xenografts. (B) Tumor volume growth curves for individual mice in each treatment group. (C) Final tumor volumes for individual mice on day 17. Data are shown both as individual values and as mean ± SD. (D) Area under the curve (AUC) values reflecting the entire tumor growth curve for individual mice in each treatment group. Data are shown both as individual AUC values and as mean ± SD. ∗∗∗P < .001; ∗∗∗∗P < .0001.